Hematopoietic stem and progenitor cells regulate the regeneration of their niche by secreting Angiopoietin-1
Abstract
Hematopoietic stem cells (HSCs) are maintained by a perivascular niche in bone marrow but it is unclear whether the niche is reciprocally regulated by HSCs. Here, we systematically assessed the expression and function of Angiopoietin-1 (Angpt1) in bone marrow. Angpt1 was not expressed by osteoblasts. Angpt1 was most highly expressed by HSCs, and at lower levels by c-kit+ hematopoietic progenitors, megakaryocytes, and Leptin Receptor+ (LepR+) stromal cells. Global conditional deletion of Angpt1, or deletion from osteoblasts, LepR+ cells, Nes-cre-expressing cells, megakaryocytes, endothelial cells or hematopoietic cells in normal mice did not affect hematopoiesis, HSC maintenance, or HSC quiescence. Deletion of Angpt1 from hematopoietic cells and LepR+ cells had little effect on vasculature or HSC frequency under steady-state conditions but accelerated vascular and hematopoietic recovery after irradiation while increasing vascular leakiness. Hematopoietic stem/progenitor cells and LepR+ stromal cells regulate niche regeneration by secreting Angpt1, reducing vascular leakiness but slowing niche recovery.
https://doi.org/10.7554/eLife.05521.001eLife digest
In adults, blood cells develop from a set of stem cells that are found in bone marrow. There are also specialized blood vessels and cells called ‘stromal cells’ within the bone marrow that provide these stem cells with oxygen, nutrients, and other molecules. This local environment, or ‘niche’, plays an important role in regulating the maintenance of these stem cells. But it has not been known whether stem cells can reciprocally regulate their niches.
Unfortunately, radiation used to treat cancer obliterates the stem cells and their niche; both must recover after such a treatment before the patient can produce blood cells normally again. A protein called Angpt1 is thought to play a role in this post-treatment recovery. Angpt1 is known to regulate blood vessels in the bone marrow, and one influential study had previously suggested that bone cells produce Angpt1, which promotes and regulates the maintenance of the stem cells within the niche. However, this previous study did not directly test this. Thus, it was not clear whether Angpt1 promotes the regeneration of the stem cells themselves or if it regulates the rebuilding of the niche.
Now, Zhou, Ding and Morrison have genetically engineered mice to make a ‘reporter’ molecule—which glows green when viewed under a microscope—wherever and whenever the gene for Angpt1 is active. These experiments showed where the protein is produced, and unexpectedly revealed that the bone cells do not make Angpt1. Instead, it is the stem cells and the stromal cells in the niche that made the protein. Further experiments showed that deleting the gene for Angpt1 from mice, or just from their bone cells, did not affect blood cell production; nor did it affect the maintenance or regulation of the stem cells.
Next, Zhou, Ding and Morrison looked at whether Angpt1 might be involved in rebuilding the niche after being exposed to radiation. Some of these irradiated mice had been genetically engineered to lack Angpt1; and, in these mice, blood stem cells and blood cell production recovered more quickly than in mice with Angpt1. The blood vessels in the niche also grew back more quickly in the irradiated mice that lacked Angpt1. However, these regenerated blood vessels were leaky. This suggests that blood stem cells produce Angpt1 to slow the recovery of the niche and reduce leakage from the blood vessels. Thus, blood stem cells can regulate the regeneration of the niches that maintain them.
https://doi.org/10.7554/eLife.05521.002Introduction
Hematopoietic stem cells (HSCs) reside in a specialized bone marrow niche in which Leptin Receptor+ (LepR+) perivascular stromal cells and endothelial cells secrete factors that promote their maintenance (Kobayashi et al., 2010; Ding et al., 2012; Ding and Morrison, 2013; Greenbaum et al., 2013; Poulos et al., 2013; Morrison and Scadden, 2014). Nearly all the cells that express high levels of Scf (Kitl) or Cxcl12 in the bone marrow are LepR+ (Zhou et al., 2014). Conditional deletion of Scf from LepR+ cells and endothelial cells leads to loss of all quiescent and serially-transplantable HSCs from adult bone marrow (Oguro et al., 2013). These LepR+ niche cells have also been identified based on their expression of high levels of Cxcl12 (Sugiyama et al., 2006; Ding and Morrison, 2013; Omatsu et al., 2014), low levels of the Nestin-GFP transgene (Mendez-Ferrer et al., 2010; Kunisaki et al., 2013), PDGFRα (Morikawa et al., 2009; Zhou et al., 2014), and Prx1-Cre (also known as Prrx1-Cre) (Greenbaum et al., 2013). Consistent with the conclusion that HSC niche cells include mesenchymal stem/stromal cells (Sacchetti et al., 2007; Mendez-Ferrer et al., 2010), the LepR+ cells are highly enriched for CFU-F and give rise to most of the osteoblasts and fat cells that form in adult bone marrow (Zhou et al., 2014).
Angpt1 has been proposed to be expressed by osteoblasts in the bone marrow and to promote the maintenance of quiescent HSCs in an osteoblastic niche (Arai et al., 2004). However, HSCs and perivascular stromal cells also express Angpt1 (Takakura et al., 2000; Ivanova et al., 2002; Forsberg et al., 2005; Kiel et al., 2005; Sacchetti et al., 2007; Ding et al., 2012). Moreover, it has not been tested whether Angpt1 deficiency affects HSC function in vivo. Thus, the physiological function and sources of Angpt1 in the bone marrow remain uncertain.
Angpt1 (Suri et al., 1996), and its receptor Tie2 (Dumont et al., 1994; Puri et al., 1995; Sato et al., 1995; Davis et al., 1996), are necessary for embryonic vascular development. Tie2 is mainly expressed by endothelial cells (Schnurch and Risau, 1993; Kopp et al., 2005) but also by HSCs (Iwama et al., 1993; Arai et al., 2004). Angpt1 over-expression promotes the development of larger, more numerous, more highly branched, and less leaky blood vessels (Suri et al., 1998; Thurston et al., 1999; Cho et al., 2005). Angpt1 expression by primitive hematopoietic progenitors (HPCs) promotes angiogenesis during embryonic development (Takakura et al., 2000). Global conditional deletion of Angpt1 between embryonic day (E)10.5 and E12.5 increases the size and number of blood vessels in fetal tissues but later deletion has little effect on vascular development (Jeansson et al., 2011). Nonetheless, Angpt1 does regulate angiogenesis in response to a variety of injuries in adult tissues (Kopp et al., 2005; Jeansson et al., 2011; Lee et al., 2013), promoting angiogenesis in some contexts (Thurston et al., 1999) while negatively regulating angiogenesis in other contexts (Visconti et al., 2002; Augustin et al., 2009; Jeansson et al., 2011; Lee et al., 2014). A key function of Angpt1 is to reduce the leakiness of blood vessels, perhaps by tightening junctions between endothelial cells (Thurston et al., 1999; Brindle et al., 2006; Lee et al., 2013, 2014).
Irradiation and chemotherapy not only deplete HSCs but also disrupt their niche in the bone marrow, particularly the sinusoids (Knospe et al., 1966; Kopp et al., 2005; Li et al., 2008; Hooper et al., 2009) around which most HSCs (Kiel et al., 2005) as well as Scf-, Cxcl12-, and LepR-expressing stromal cells reside (Ding et al., 2012; Ding and Morrison, 2013; Omatsu et al., 2014; Zhou et al., 2014). Regeneration of this perivascular niche after injury, including endothelial and stromal components, is necessary for regeneration of HSCs and hematopoiesis (Kopp et al., 2005; Hooper et al., 2009). After 5-fluorouracil treatment, Tie2 signaling (which is regulated by its ligands Angpt1, Angpt2, and possibly Angpt3 [Augustin et al., 2009; Eklund and Saharinen, 2013; Fagiani and Christofori, 2013; Thomson et al., 2014]) regulates the remodeling of blood vessels in the bone marrow and adenoviral over-expression of Angpt1 accelerates the recovery of hematopoiesis (Kopp et al., 2005). This raises the question of whether endogenous Angpt1 is necessary for niche recovery and whether it acts by promoting HSC function in an osteoblastic niche or by regulating vascular regeneration.
Results
Angpt1 is expressed by megakaryocytes, HSCs, c-kit+ cells, and LepR+ stromal cells
We first assessed the Angpt1 expression using a commercially available antibody to stain bone marrow sections. Most bone marrow cells did not stain positively and we were unable to detect any staining among bone-lining cells where osteoblasts localize (Figure 1A–C). The most prominent staining was in large CD41+ megakaryocytes (Figure 1D–F) and in c-kit+ HPCs (Figure 1G–I).
To analyze Angpt1 expression by flow cytometry, we generated Angpt1GFP knock-in mice by recombining GFP into the endogenous Angpt1 locus (Figure 1—figure supplement 1A–D). Consistent with the antibody staining pattern, GFP was expressed by CD41+ megakaryocytes (Figure 1J–L) and c-kit+ HPCs throughout bone marrow (Figure 1M–O). By flow cytometry, only 1.5 ± 0.8% of mechanically dissociated bone marrow cells (which include few stromal cells) were GFP+ (Figure 1P). Overall, 85% of GFP+ hematopoietic cells were c-kit+ (Figure 1—figure supplement 1E): 72 ± 13% of c-kit+ cells were GFP+ and only 1.3 ± 0.7% of c-kit− cells were GFP+ (Figure 1Q,R). All CD150+CD48−LSK HSCs expressed high levels of GFP (Figure 1S). All CD150−CD48−LSK multipotent progenitors (MPPs) were also positive for GFP, though at somewhat lower levels per cell than HSCs (Figure 1T). Virtually all CD48+LSK HPCs, Lineage−Sca1lowc-kitlowFlt3+IL7Rα+ common lymphoid progenitors (CLPs; Kondo et al., 1997), CD34+FcγR−Lineage−Sca1−c-kit+ common myeloid progenitors (CMPs; Akashi et al., 2000), and CD34+FcγR+Lineage−Sca1−c-kit+ granulocyte-monocyte progenitors (GMPs; Akashi et al., 2000) were GFP+ but with successively lower expression levels per cell relative to HSCs (Figure 1U–X). Few CD34−FcγR−Lineage−Sca1−c-kit+ megakaryocyte-erythroid progenitors (MEPs; Akashi et al., 2000) were positive for GFP (Figure 1Y). Angpt1 was thus broadly expressed by early HPCs, at levels that declined as progenitors matured.
Virtually all of the Angpt1 expression by stromal cells in the bone marrow was by LepR+ cells. GFP+LepR+ stromal cells localized mainly around sinusoids throughout the bone marrow (Figure 2A–C) but were also present near arterioles (data not shown). GFP was expressed by 94 ± 3.2% of LepR+ stromal cells and 94 ± 2.5% of GFP+ stromal cells (CD45−Ter119−) were LepR+ (Figure 2F). Consistent with this, nearly all GFP+ stromal cells were PDGFRα+, a marker of mesenchymal stem/stromal cells (Morikawa et al., 2009) expressed by LepR+ bone marrow cells (Zhou et al., 2014). Nearly all PDGFRα+ cells were GFP+ (Figure 2G). Consistent with an earlier report (Sacchetti et al., 2007), this suggests that Angpt1 is widely expressed by mesenchymal stem/stromal cells in the bone marrow as LepR+ cells exhibit most of the CFU-F and osteogenic activity in adult mouse bone marrow (Zhou et al., 2014). We were unable to detect GFP expression by endothelial cells (Figure 2H), or by Osteopontin+ bone lining cells in the diaphysis (Figure 2D) or metaphysis (Figure 2E). Quantitative RT-PCR (qRT-PCR) analysis found that the highest levels of Angpt1 in the bone marrow were in HSCs (350-fold higher than whole bone marrow cells [WBM]), followed by LepR+ stromal cells (200-fold higher than WBM), LSK primitive HPCs (120-fold), c-kit+ HPCs (60-fold), and megakaryocytes (70-fold; Figure 2I).
Consistent with prior studies (Iwama et al., 1993; Schnurch and Risau, 1993; Arai et al., 2004; Kopp et al., 2005), qRT-PCR showed that the Angpt1 receptor, Tie2, was expressed most prominently by endothelial cells (167-fold higher than WBM) and HSCs (21-fold higher; Figure 2J). Tie2 protein was expressed by most c-kit+ HPCs and endothelial cells in normal adult bone marrow and after irradiation (Figure 6—figure supplement 2).
Angpt1 is not required for HSC maintenance
To study Angpt1 function under physiological conditions in adult bone marrow, we generated a floxed allele of Angpt1 (Angpt1fl) (Figure 3—figure supplement 1A–C) and an Angpt1 deficient allele (Angpt1−) by recombining Angpt1fl in the germline using CMV-cre. Consistent with the embryonic lethal phenotype of two independent Angpt1 null alleles that were previously described (Suri et al., 1996; Jeansson et al., 2011), the mating of Angpt1+/− heterozygous mice did not lead to the birth of any Angpt1−/− pups (Figure 3—figure supplement 1D). Angpt1−/− embryos were found dead when timed pregnancies were examined at E12.5 (data not shown). Angpt1 transcripts could not be detected in the fetal livers of Angpt1−/− mice (Figure 3—figure supplement 1E). Thus, germline recombination of the Angpt1fl allele leads to a severe loss of Angpt1 function.
We conditionally deleted Angpt1 from osteoblasts using Col1a1*2.3-cre; Angpt1fl/fl mice. Col1a1*2.3-cre recombines efficiently in fetal and postnatal osteoblasts (Liu et al., 2004; Ding et al., 2012). Col1a1*2.3-cre deleted 94 ± 3.0% of Angpt1fl alleles in Col1a1*2.3-GFP+ osteoblasts from Col1a1*2.3-cre; Angpt1fl/fl; Col1a1*2.3-GFP mice (Figure 3—figure supplement 2A). Ten to 13 week-old adult Col1a1*2.3-cre; Angpt1fl/fl mice had normal blood cell counts (Figure 3—figure supplement 2B), normal lineage composition in bone marrow, spleen and thymus (Figure 3—figure supplement 2C), and normal cellularity in the bone marrow, spleen and thymus (Figure 3A and Figure 3—figure supplement 2D). CD150+CD48−LSK HSC frequency was normal in the bone marrow and spleens of Col1a1*2.3-cre; Angpt1fl/fl mice relative to littermate controls (Figure 3B). Col1a1*2.3-cre; Angpt1fl/fl bone marrow cells also had normal frequencies of CLPs (Figure 3—figure supplement 2E), colony-forming progenitors in culture (Figure 3C) and dividing HSCs that incorporated BrdU (5'-bromo-2'-deoxyuridine) over 10 days in vivo (Figure 3D). Col1a1*2.3-cre; Angpt1fl/fl and control bone marrow cells gave rise to similar levels of long-term multilineage reconstitution upon transplantation into irradiated mice (Figure 3E).
To further test whether osteolineage progenitors are a source of Angpt1 for HSC maintenance, we deleted Angpt1 using Osx-Cre (Sp7-Cre) (Rodda and McMahon, 2006). Osx-Cre recombined 93% of Angpt1fl alleles from CD105+PDGFRα+CD45−Ter119−CD31− osteoprogenitors (Park et al., 2012) in Osx-cre; Angpt1fl/fl mice (Figure 4A). Osx-cre; Angpt1fl/fl mice also had normal blood cell counts (Figure 4B), normal cellularity, and HSC frequency in the bone marrow and spleen (Figure 4C,D), normal frequencies of colony-forming progenitors in culture (Figure 4E) and normal levels of long-term multilineage reconstitution upon transplanting bone marrow cells into irradiated mice (Figure 4F). Angpt1 from osteoblasts and their restricted progenitors are thus not required for hematopoiesis or HSC maintenance in normal adult mice.
To test whether Angpt1 from LepR+ stromal cells is required for HSC maintenance we generated Leprcre; Angpt1fl/fl or Leprcre; Angpt1fl/GFP mice. Lepr-Cre deleted 91% of Angpt1fl alleles in LepR+ bone marrow stromal cells from Leprcre; Angpt1fl/GFP mice (Figure 3—figure supplement 2F). At 8 to 13 weeks of age, Leprcre; Angpt1fl/GFP mice had normal blood cell counts (Figure 3—figure supplement 2G), normal lineage composition in bone marrow and spleen (data not shown), and normal cellularity in the bone marrow and spleen (Figure 3F). They also had normal frequencies of CD150+CD48−LSK HSCs in the bone marrow and spleen (Figure 3G), colony-forming progenitors in bone marrow (Figure 3H), and dividing HSCs (Figure 3I). Leprcre; Angpt1fl/GFP and control bone marrow cells gave rise to similar levels of long-term multilineage reconstitution upon transplantation into irradiated mice (Figure 3J). Angpt1 from LepR+ stromal cells is thus not required for hematopoiesis, HSC maintenance, or HSC quiescence in normal adult mice. Similar results were obtained from adult Nestin-cre; Angpt1fl/fl mice (Figure 4G–K).
To test if Angpt1 expressed by hematopoietic cells regulates HSC function we generated Mx1-cre; Angpt1fl/fl mice. pIpC (polyinosinic-polycytidylic acid) was administered to mice at 2 months of age then the mice were examined 3 months later. We observed complete recombination in 98% of colonies formed by HSCs in culture (Figure 3—figure supplement 2H). Mx1-cre; Angpt1fl/fl mice had normal blood cell counts (Figure 3—figure supplement 2I), normal lineage composition in bone marrow and spleen (data not shown), and normal bone marrow and spleen cellularity (Figure 3K). Mx1-cre; Angpt1fl/fl mice also had normal frequencies of CD150+CD48−LSK HSCs in the bone marrow and spleen (Figure 3L), colony-forming progenitors in bone marrow (Figure 3M), and dividing HSCs that incorporated BrdU during a 10-day pulse (Figure 3N). Mx1-cre; Angpt1fl/fl and control bone marrow cells gave rise to similar levels of long-term multilineage reconstitution upon transplantation into irradiated mice (Figure 3O). Similar results were obtained when we conditionally deleted Angpt1 from fetal hematopoietic and endothelial cells by generating Tie2-cre; Angpt1fl/fl mice (Figure 5A–G) and when we conditionally deleted Angpt1 from megakaryocytes by generating Pf4-cre; Angpt1fl/fl mice (Figure 5H–K). Angpt1 from endothelial cells and hematopoietic cells, including megakaryocytes, is thus not required for hematopoiesis, HSC maintenance, or HSC quiescence in normal adult mice.
To globally delete Angpt1 we generated UBC-cre/ER; Angpt1fl/fl mice. UBC-Cre/ER ubiquitously recombines in adult mice upon tamoxifen administration (Ruzankina et al., 2007). We administrated tamoxifen-containing chow to 8-week old UBC-cre/ER; Angpt1fl/fl mice as well as littermate controls for 2–5 months then sacrificed them for analysis. UBC-cre/ER recombined 95% of Angpt1fl alleles in LSK cells and 96% of Angpt1fl alleles in LepR+ cells in the bone marrow of UBC-cre/ER; Angpt1fl/fl mice (Figure 3—figure supplement 2K). UBC-cre/ER; Angpt1fl/fl mice had normal blood cell counts (Figure 3—figure supplement 2L), normal bone marrow and spleen hematopoietic lineage composition (data not shown) and normal bone marrow and spleen cellularity relative to controls (Figure 3P). UBC-cre/ER; Angpt1fl/fl mice also had normal frequencies of CD150+CD48−LSK HSCs in the bone marrow and spleen (Figure 3Q), colony-forming progenitors in bone marrow (Figure 3R), and long-term multilineage reconstituting bone marrow cells upon transplantation into irradiated mice (Figure 3S). Angpt1 is thus dispensable for hematopoiesis and for the maintenance and function of HSCs in normal adult mice.
Angpt1 from LepR+ cells and hematopoietic stem/progenitor cells delays HSC regeneration after irradiation
We next tested whether Angpt1 regulates the recovery of hematopoiesis after irradiation. Since hematopoietic cells (HSCs, c-kit+ HPCs, and megakaryocytes) and LepR+ stromal cells were the major sources of Angpt1 in the bone marrow (Figures 1, 2) we reconstituted irradiated Leprcre; Angpt1fl/GFP or control recipients by transplanting 1 × 106 mechanically dissociated bone marrow cells from Mx1-cre; Angpt1fl/fl or control donors 1 month after pIpC treatment. This allowed us to test whether Angpt1 from LepR+ stromal cells and/or hematopoietic cells influenced the regeneration of hematopoiesis after irradiation.
We did not detect significant changes in the patterns of Angpt1, Tie2, or Angpt2 expression in the bone marrow after irradiation and bone marrow transplantation (Figure 6—figure supplement 2). In both normal adult bone marrow, and after irradiation and transplantation, Tie2 was expressed primarily by endothelial cells and c-kit+ HPCs (Figure 6—figure supplement 2G) while Angpt2 was expressed primarily by endothelial cells.
As expected, non-irradiated adult Leprcre; Angpt1fl/GFP mice, Mx1-cre; Angpt1fl/fl mice, and Leprcre; Mx1-cre; Angpt1fl/GFP mice all had normal bone marrow cellularity (Figure 6A), normal numbers of LSK cells in the bone marrow (Figure 6B), and normal CD150+CD48−LSK HSC frequency (Figure 6C). However, at 8 and 12 days after irradiation, Leprcre; Angpt1fl/GFP mice that had been transplanted with Mx1-cre; Angpt1fl/fl bone marrow cells, and to a significantly lesser extent Leprcre; Angpt1fl/GFP mice that had been transplanted with wild-type bone marrow cells, exhibited significantly higher bone marrow cellularity (Figure 6A) and significantly higher numbers of LSK cells in the bone marrow (Figure 6B) as compared to wild-type mice transplanted with wild-type bone marrow cells. At 16 days after irradiation, most of these differences persisted but by 28 days after irradiation mice in all treatments had similar bone marrow cellularities and LSK (Lineage−Sca1+c-kit+ cells) numbers (Figure 6A,B). The accelerated recovery of HPCs and hematopoiesis in the absence of Angpt1 was also evident in white blood cell counts and in the numbers of myeloid, lymphoid, and erythroid cells in the bone marrow (Figure 6—figure supplement 1). Angpt1 expression by hematopoietic cells and LepR+ stromal cells therefore negatively regulates the recovery of hematopoiesis after irradiation.
We tested whether Angpt1 also influenced the expansion of HSC numbers after irradiation by transplanting WBMs from mice in each of the treatments described above at 12 days after transplantation. Bone marrow cells from Leprcre; Angpt1fl/GFP mice transplanted with Mx1-cre; Angpt1fl/fl bone marrow gave significantly higher levels of donor cell reconstitution in all lineages as compared to bone marrow cells from wild-type mice transplanted with wild-type bone marrow (Figure 6D). To a lesser extent, bone marrow cells from Leprcre; Angpt1fl/GFP mice that had been transplanted with wild-type bone marrow also gave significantly higher levels of donor cell reconstitution as compared to bone marrow cells from wild-type mice transplanted with wild-type bone marrow (Figure 6D). The expansion in HSC numbers during reconstitution is thus negatively regulated by Angpt1 expressed by hematopoietic cells and LepR+ stromal cells.
Since WBMs could potentially contain Angpt1-expressing stromal cells in addition to hematopoietic stem/progenitor cells and megakaryocytes we undertook a series of additional experiments to test whether hematopoietic stem/progenitor cells are a functionally important source of Angpt1 for hematopoietic regeneration. First, we transplanted 4000 LSK (Lineage−Sca-1+c-kit+) cells from control or Mx1-cre; Angpt1fl/fl mice into Leprcre; Angpt1GFP/fl mice to test the effects of HPCs uncontaminated by stromal cells on hematopoietic regeneration after irradiation. We found that the mice transplanted with Angpt1 deficient LSK cells had significantly higher bone marrow cellularity (Figure 6E) and LSK cell numbers (Figure 6F) than mice transplanted with control LSK cells at 14 days after irradiation. These data prove that Angpt1 expression by hematopoietic cells regulates hematopoietic recovery after irradiation.
The only hematopoietic cells other than c-kit+ hematopoietic stem and progenitor cells that express Angpt1 are megakaryocytes (Figure 1D–F,J–L). To test whether Angpt1 expression by megakaryocytes contributes to the regulation of hematopoietic recovery we conditionally deleted Angpt1 from megakaryocyte lineage cells using Pf4-Cre and transplanted WBMs from control and Pf4-cre; Angpt1fl/fl mice into Leprcre; Angpt1GFP/fl recipients. We did not detect any significant differences in hematopoietic recovery between mice transplanted with control vs Pf4-cre; Ang1fl/fl bone marrow (Figure 6G,H). These data indicate that Angpt1 expression by megakaryocyte lineage cells has little effect on hematopoietic recovery after irradiation. Together, our data demonstrate that Angpt1 expression by hematopoietic stem and progenitor cells and LepR+ stromal cells regulate hematopoietic recovery after irradiation.
Angpt1 from LepR+ cells and hematopoietic stem/progenitor cells delays vascular regeneration after irradiation
Consistent with a prior study (Jeansson et al., 2011), loss of Angpt1 expression in the bone marrow had no detectable effect on the bone marrow vasculature in normal young adult mice. Deletion of Angpt1 from hematopoietic cells in Mx1-cre; Angpt1fl/fl mice, or perivascular stromal cells in Leprcre; Angpt1fl/GFP mice, or both in Mx1-cre; Leprcre; Angpt1fl/GFP mice, did not affect the numbers of VE-cadherin+ endothelial cells or LepR+ perivascular cells in the bone marrow (Figure 7A,B), or the density or morphology of the vasculature in bone marrow relative to control mice (Figure 7—figure supplement 1A).
Irradiation induces vascular regression followed by regeneration from surviving endothelial cells (Heissig et al., 2005; Kopp et al., 2005; Li et al., 2008; Hooper et al., 2009). Consistent with this we observed dilated regressed sinusoids throughout the bone marrow 8 days after irradiation and bone marrow transplantation (compare Figure 7C–F,J). Few hematopoietic cells clustered around these regressed sinusoids relative to normal bone marrow (compare Figure 7C–F). Morphologically normal, hematopoietic cell-invested sinusoids were evident in some areas of the bone marrow 12 days after transplantation (Figure 7G,J), and their frequency increased 16 days after transplantation (Figure 7H,J). By day 28, regressed vessels were no longer observed in the bone marrow in any treatment (Figure 7I,J).
When Mx1-cre; Angpt1fl/fl bone marrow cells were transplanted into wild-type recipients (Mx1 → Cre−), vascular recovery was indistinguishable from control mice (Cre− → Cre−) (Figure 7G,J and Figure 7—figure supplement 1). However, when wild-type bone marrow cells were transplanted into Leprcre; Angpt1fl/GFP recipients (Cre− → Lepr) we observed accelerated morphological recovery of the vasculature, with significantly fewer dilated regressed vessels at 12 and 16 days after transplantation relative to control mice (Figure 7G,J and Figure 7—figure supplement 1C). The accelerated recovery was significantly more pronounced when we transplanted Mx1-cre; Angpt1fl/fl bone marrow cells into Leprcre; Angpt1fl/GFP recipients (Mx1 → Lepr). These mice exhibited significantly fewer regressed vessels at 12 and 16 days after transplantation relative to control mice and Cre− → Lepr mice (Figure 7G,J and Figure 7—figure supplement 1C). By 28 days after irradiation mice in all treatments had reacquired morphologically normal bone marrow vasculature (Figure 7I,J and Figure 7—figure supplement 1D). These data indicate that Angpt1 produced by hematopoietic cells and LepR+ stromal cells slows the morphological recovery of blood vessels after irradiation. When combined with the observation that Angpt1 also slows the regeneration of HSCs (Figure 6B,D) and bone marrow hematopoiesis (Figure 6A) after irradiation, the data indicate that Angpt1 negatively regulates the regeneration of the HSC niche in bone marrow after irradiation.
We transplanted 4000 LSK cells from control and Mx1-cre; Angpt1fl/fl mice into Leprcre; Angpt1GFP/fl mice to test the effects of HPCs uncontaminated by stromal cells on vascular regeneration after irradiation. We found that the mice transplanted with Angpt1 deficient LSK cells had significantly better vascular morphology in the bone marrow (Figure 7L,M) than mice transplanted with control LSK cells at 14 days after irradiation. To test whether Angpt1 expression by megakaryocytes contributed to the vascular recovery we transplanted WBMs from control and Pf4-cre; Angpt1fl/fl mice into Leprcre; Angpt1GFP/fl recipients. We did not detect any significant differences in vascular recovery between mice transplanted with control vs Pf4-cre; Ang1fl/fl bone marrow (Figure 7N,O). Angpt1 expression by hematopoietic stem and progenitor cells and LepR+ stromal cells therefore regulate both hematopoietic and vascular recovery after irradiation.
To investigate the cellular mechanism by which Angpt1 influences vascular recovery after irradiation we assessed the proliferation of bone marrow endothelial cells. In normal adult bone marrow few endothelial cells incorporated a 24-hr pulse of BrdU and deletion of Angpt1 from hematopoietic cells, LepR+ cells, or both did not influence this frequency (Figure 7K). After irradiation and bone marrow transplantation, endothelial cells were recruited into cycle (Figure 7K). Deletion of Angpt1 from hematopoietic cells and LepR+ cells significantly increased the frequency of dividing endothelial cells 12 days after transplantation (Figure 7K). These data suggest that Angpt1 slows the recovery of the vasculature and the HSC niche partly by negatively regulating the proliferation of endothelial cells after irradiation.
Angpt1 from LepR+ cells and hematopoietic stem/progenitor cells promotes vascular integrity during regeneration
To test whether Angpt1 regulates vascular leakiness in the bone marrow we assessed Evans blue extravasation. Evans blue binds to serum albumin and can be used to trace macromolecule flux across blood vessels (Radu and Chernoff, 2013). In normal bone marrow we observed little Evans blue extravasation, irrespective of whether Angpt1 was deleted from hematopoietic cells, LepR+ cells, or both (Figure 8A), suggesting that Angpt1 is dispensable for maintaining vascular integrity in normal adult bone marrow. In contrast, 12 days after irradiation we observed uniformly high levels of Evans blue extravasation in bone marrow from mice in all treatments (Figure 8A and Figure 8—figure supplement 1A), consistent with the leakiness that would be expected from regenerating blood vessels (Hooper et al., 2009). When morphological recovery of bone marrow vessels was complete 28 days after irradiation (Figure 7J and Figure 7—figure supplement 1D), control mice (Cre− → Cre−) and wild-type mice transplanted with Angpt1 deficient bone marrow cells (Mx1 → Cre−) had largely re-established vascular integrity, with little Evans blue extravasation (Figure 8A). Leprcre; Angpt1fl/GFP mice transplanted with wild-type bone marrow cells (Cre− → Lepr) showed a trend toward increased Evans blue extravasation but the effect was not statistically significant relative to control mice (Figure 8A). In contrast, Leprcre; Angpt1fl/GFP mice transplanted with Angpt1 deficient bone marrow cells (Mx1 → Lepr) exhibited significantly higher levels of Evans blue extravasation at 28 days after transplantation (Figure 8A). Leaky vasculature was not observed in the spleen (Figure 8—figure supplement 1B). Angpt1 from hematopoietic cells and LepR+ stromal cells is thus required to promote vascular integrity in the bone marrow after regeneration at the expense of slowing endothelial cell proliferation and the morphological recovery of blood vessels, slowing the regeneration of the HSC niche.
To independently assess vascular integrity, we performed live imaging of the vasculature in the calvarium bone marrow of mice intravenously administered anti-VE-cadherin antibody and dextran-FITC (70 kDa). In normal mice, dextran-FITC fluorescence was tightly restricted within VE-cadherin+ vessels (Figure 8—figure supplement 1C). 12 days after irradiation, calvarium blood vessels became dilated and dextran-FITC leaked throughout the medullary cavity (Figure 8—figure supplement 1D). At 28 days after transplantation, control mice (Cre− → Cre−), wild-type mice transplanted with Angpt1 deficient hematopoietic cells (Mx1 → Cre−), and Leprcre; Angpt1fl/GFP mice transplanted with wild-type bone marrow cells (Cre− → Lepr) all exhibited vascular integrity, with little discernible leakage of dextran-FITC (Figure 8D). In contrast, Leprcre; Angpt1fl/GFP mice transplanted with Angpt1 deficient bone marrow cells (Mx1 → Lepr) exhibited leaky vessels in the calvarium with dextran-FITC infiltrating the bone marrow (Figure 8D, see arrows). Thus, consistent with the Evans blue assay, Angpt1 from hematopoietic cells and LepR+ cells promotes bone marrow vascular integrity during regeneration.
We transplanted 4000 LSK cells from control and Mx1-cre; Angpt1fl/fl mice into Leprcre; Angpt1GFP/fl mice to test the effects of HPCs uncontaminated by stromal cells on vascular integrity after irradiation. The mice transplanted with Angpt1 deficient, but not control, LSK cells exhibited vascular leakage in the bone marrow 28 days after irradiation, as evidenced by high level of Evans blue and Dextran-FITC extravasation (Figure 8B,E). To test whether Angpt1 expression by megakaryocytes contributed to the vascular integrity we transplanted WBMs from control and Pf4-cre; Angpt1fl/fl mice into Leprcre; Angpt1GFP/fl recipients. We did not detect any significant differences in vascular leakiness between mice transplanted with control vs Pf4-cre; Ang1fl/fl bone marrow (Figure 8C,F). Angpt1 expression by hematopoietic stem and progenitor cells and LepR+ stromal cells therefore promotes vascular integrity during regeneration after irradiation.
We performed scanning electron microscopy to better understand the loss of blood vessel integrity after Angpt1 deletion. Normal bone marrow sinusoids were 5–20 µm in luminal diameter (Figure 8—figure supplement 1E). They could be readily distinguished from bone marrow arterioles, which had thicker walls and a different morphology (Figure 8—figure supplement 1G). At 8–16 days after irradiation, sinusoid diameter in the bone marrow increased (compare Figure 8—figure supplement 1E,F) and the endothelial lining was marked by small pores (Figure 8—figure supplement 1F), consistent with the finding that irradiation causes discontinuities in bone marrow blood vessels (Daldrup et al., 1999). At 28 days after irradiation, pores were rare in sinusoids from wild-type mice transplanted with wild-type marrow (Cre− → Cre−), wild-type mice transplanted with Angpt1 deficient bone marrow (Mx1 → Cre−), and Leprcre; Angpt1fl/GFP mice transplanted with wild-type bone marrow (Cre− → Lepr) (Figure 8G,H), consistent with the integrity of vessels in these mice. In contrast, pores remained common in blood vessels in bone marrow from Leprcre; Angpt1fl/GFP mice transplanted with Angpt1 deficient bone marrow cells (Mx1 → Lepr) (Figure 8H, see arrow; Figure 8G). These data suggest that in the absence of Angpt1, vascular integrity is reduced in regenerating bone marrow blood vessels because of the persistence of pores or discontinuities among endothelial cells.
Vascular leakiness does not accelerate hematopoietic recovery
To test whether the accelerated hematopoietic recovery in the absence of Angpt1 is caused by the increase in vascular leakiness we treated mice with cavtratin, an anti-permeability agent unrelated to Angpt1 function (Gratton et al., 2003). We injected cavtratin (2.5 mg/kg/day i.p.) into control (control bone marrow transplanted into control mice) and Mx1 → Lepr recipients from 7 to 13 days after irradiation then analyzed the mice 14 days after irradiation and bone marrow transplantation. Based on both Dextran-FITC live-imaging and Evans blue extravasation, cavtratin significantly reduced vascular leakiness in both control and Mx1 → Lepr recipient mice (Figure 9A,B). However, cavtratin administration did not significantly affect the recovery of bone marrow cellularity or LSK cell numbers in the bone marrow of control or Mx1 → Lepr recipients (Figure 9C,D). Mx1 → Lepr recipients continued to regenerate bone marrow cellularity and LSK cell numbers significantly faster than control mice, irrespective of cavtratin treatment. The accelerated recovery of hematopoietic stem/progenitor cells and hematopoiesis in the absence of Angpt1 is therefore not caused by increased vascular leakiness. These appear to reflect independent effects of Angpt1.
Discussion
Several gene-expression profiling studies are consistent with our finding that HSCs are a major source of Angpt1 (Ivanova et al., 2002; Akashi et al., 2003; Forsberg et al., 2010; Cabezas-Wallscheid et al., 2014). In addition, an Angpt1-LacZ knockin allele is expressed in an HSC-enriched population (Takakura et al., 2000). Several prior studies have also demonstrated that perivascular stromal cells are a significant source of Angpt1 in the bone marrow (Sacchetti et al., 2007; Mendez-Ferrer et al., 2010; Ding et al., 2012). In contrast, we have been unable to detect Angpt1 expression in osteoblasts in Angpt1GFP knock-in mice (Figure 2D,E), by anti-Angpt1 antibody staining (Figure 1A–C), by qRT-PCR on sorted cells (Figure 2I), or by gene-expression profiling of osteoblasts (data not shown). Megakaryocytes also express Angpt1 (Figure 1J–L) but unlike deletion in hematopoietic stem/progenitor cells and LepR+ stromal cells, conditional deletion in megakaryocyte lineage cells did not affect hematopoietic or vascular regeneration after irradiation (Figures 6–9). Thus, hematopoietic stem/progenitor cells and LepR+ stromal cells are the functionally important sources of Angpt1 in the bone marrow.
Tie1 and Tie2 are the receptors for Angpt1, Angpt2, and possibly Angpt3 (Augustin et al., 2009; Eklund and Saharinen, 2013; Fagiani and Christofori, 2013; D'Amico et al., 2014; Thomson et al., 2014). Tie1 is not required for the development or maintenance of fetal liver or adult bone marrow HSCs (Corash et al., 1989; Rodewald and Sato, 1996). Tie1/Tie2 double knockout ES cells contribute to fetal but not adult hematopoiesis (Puri and Bernstein, 2003). Given that Angpt1 is not required for the maintenance of adult hematopoiesis, some combination of Angpt2 and Angpt3 may be required for adult hematopoiesis.
Global Angpt1 deletion (Figure 3P–S), deletion from osteoblasts and their progenitors (Figure 3A–E and Figure 4A–F), or deletion from hematopoietic and/or LepR+ stromal cells (Figure 3F–O), did not affect HSC frequency or HSC function in normal adult mice. Angpt1 deletion from these cell populations had little effect on the bone marrow vasculature in normal adult mice (Figures 7, 8). We observed only rare pores in sinusoidal epithelium from Leprcre; Mx1-cre; Angpt1fl/GFP mice (Figure 8G,H) and virtually no Evans blue leakage (Figure 8A). In contrast, Angpt1 deletion from LepR+ stromal cells and hematopoietic cells had much larger effects on the regeneration of the vasculature and the HSC niche after irradiation. Angpt1 deficiency from these cell populations accelerated the recovery of hematopoiesis (Figure 6A), the regeneration of LSK cells (Figure 6B), the regeneration of long-term multilineage reconstituting HSCs (Figure 6D), the proliferation of endothelial cells (Figure 7K), and the morphological recovery of bone marrow blood vessels (Figure 7E–J and Figure 7—figure supplement 1). However, Angpt1 deficiency also increased the leakiness of the regenerated blood vessels (Figure 8A,D) by allowing pores to persist in sinusoidal endothelium (Figure 8G,H). Together, the data indicate that Angpt1 produced by LepR+ stromal cells and hematopoietic cells promotes vascular integrity in regenerating blood vessels in the bone marrow at the cost of slowing the regeneration of HSC niches and hematopoiesis.
Materials and methods
Mice
Targeting vectors for generating Angpt1GFP and Angpt1fl/+ mice were constructed by recombineering (Liu et al., 2003). Linearized targeting vectors were electroporated into Bruce4 ES cells. Corrected targeted ES cell clones were identified by Southern blotting and injected into C57BL/6-Tyrc-2J blastocysts. The resulting chimeric mice were bred with C57BL/6-Tyrc-2J mice to obtain germline transmission. Then the Frt-Neo-Frt cassette introduced by the targeting vector was removed by mating with Flpe mice (Rodriguez et al., 2000). These mice were backcrossed onto a C57BL/Ka background. Other mice used in this study were: Col1a1*2.3-cre (Liu et al., 2004), Leprcre (DeFalco et al., 2001), Osx-cre (Rodda and McMahon, 2006), Nestin-cre (Tronche et al., 1999), Pf4-cre (Tiedt et al., 2007), Tie2-cre (Koni et al., 2001), Mx1-cre (Kühn et al., 1995), UBC-cre/ER (Ruzankina et al., 2007), Col1a1*2.3-GFP (Kalajzic et al., 2002), Loxp-EYFP (Srinivas et al., 2001), and Loxp-tdTomato (Madisen et al., 2010). For induction of UBC-Cre/ER, Tamoxifen chow (Harlan, Indianapolis, IN) containing tamoxifen citrate at 40 mg/kg, with 5% sucrose, was administrated to mice for 2–5 months before analysis. C57BL/6-SJL (CD45.1) mice were used as recipients in transplantation experiments unless otherwise indicated. All mice were housed at the Unit for Laboratory Animal Medicine at the University of Michigan or in the Animal Resource Center at the University of Texas Southwestern Medical Center. All protocols were approved by the University of Michigan Committee on the Use and Care Animals and by the University of Texas Southwestern Institutional Animal Care and Use Committee.
Genotyping PCR
Request a detailed protocolThe following primers were used for genotyping. For Angpt1GFP, OLD308: 5′-gggaaagagtcaaacaagcag-3′ OLD309: 5′-aaccgaaagcgatcacttac-3′ and OLD292: 5′-cggacacgctgaacttgtgg-3′. For Angpt1fl, OLD335: 5′-ggactcaacttcctgggtaagc-3′ and OLD336: 5′-ggctttgacagtcaaaatgcc-3′. For Angpt1−, OLD3111: 5′-cagggttggcataaaatttgc-3′ and OLD350: 5′-tcctggtctttgcacttgactg-3′.
Quantitative reverse transcription PCR
Request a detailed protocolCells were directly sorted into Trizol. Total RNA was extracted per the manufacture's instructions. SuperScript III (Lifetech, Grand Island, NY) was used to generate cDNA. Quantitative real-time PCR was performed using SYBR green on a LightCycler 480 or Stepone Plus. β-actin amplification was used to normalize the transcript content of samples. Primers used in this study were: Angpt1: OLD7: 5′-gggggaggttggacagtaat-3′ and OLD8: 5′-catcagctcaatcctcagca-3′. Tie2: forward: 5′-gattttggattgtcccgaggtcaag-3′ and reverse: 5′-caccaatatctgggcaaatgatgg-3′. β-actin: OLD27: 5′-gctcttttccagccttcctt-3′ OLD28: 5′-cttctgcatcctgtcagcaa-3′.
Methylcellulose culture
Request a detailed protocolCells were sorted or directly pipetted into methylcellulose culture medium (3434, Stemcell Technologies, Vancouver, BC, Canada) and incubated at 37°C for 14 days in a humidified chamber.
Flow cytometry
Request a detailed protocolBone marrow cells were isolated by flushing or by crushing the long bones with a mortar and pestle in Ca2+ and Mg2+ free HBSS with 2% heat-inactivated bovine serum. Spleen cells were obtained by crushing the spleen between two glass slides. The cells were dissociated to a single cell suspension by gently passing through a 25G needle then filtering through a 70 µm nylon mesh. The following antibodies were used to isolate HSCs: anti-CD150 (TC15-12F12.2), anti-CD48 (HM48-1), anti-Sca1 (E13-161.7), anti-c-kit (2B8), and the following antibodies against lineage markers (anti-Ter119, anti-B220 [6B2], anti-Gr1 [8C5], anti-CD2 [RM2-5], anti-CD3 [17A2], anti-CD5 [53-7.3], and anti-CD8 [53-6.7]). HPCs were identified by flow cytometry using the following antibodies: anti-Sca1 (E13-161.7), anti-c-kit (2B8), and the following antibodies against lineage markers (anti-Ter119, anti-B220 [6B2], anti-Gr1 [8C5], anti-CD2 [RM2-5], anti-CD3 [17A2], anti-CD5 [53-7.3] and anti-CD8 [53-6.7]), anti-CD34 (RAM34), anti-CD135 (Flt3) (A2F10), anti-CD16/32 (FcγR) (93), anti-CD127 (IL7Rα) (A7R34), anti-CD24 (M1/69), anti-CD43 (1B11), anti-B220 (6B2), anti-IgM (II/41), anti-CD3 (17A2), anti-Gr1 (8C5), anti-Mac1 (M1/70), anti-CD41 (MWReg30), anti-CD71 (C2), anti-Ter119, anti-CD44 (IM7) and anti-CD25 (PC61). DAPI was used to exclude dead cells. Unless otherwise indicated, antibodies were obtained from eBioscience (San Diego, CA) or BD Bioscience (San Jose, CA).
For flow cytometric analysis of bone marrow stromal cells, bone marrow was flushed using HBSS with 2% bovine serum. Then, whole bone marrow was digested with DNase I (200 U/ml) and Collagenase IV (200 U/ml) or liberase (Roche, San Francisco, CA) at 37°C for 15 min. Samples were then stained with antibodies and analyzed by flow cytometry. Anti- PDGFRα (APA5), anti-CD45 (30F-11), anti-CD31 (390), and anti-Ter119 antibodies were used to isolate perivascular stromal cells. For analysis of bone marrow endothelial cells, mice were i.v. injected with 10 µg/mouse Alexa Fluor 647 conjugated anti-VE-cadherin antibody (BV13, eBiosciences) (Butler et al., 2010). 10 min later, the long bones were removed and bone marrow was flushed, digested, and stained as above. Samples were analyzed using a FACSAria or FACSCanto II flow cytometer (BD Biosciences). Data were analyzed by FACSDiva (BD Biosciences) or FlowJo (Tree Star) software.
Long-term competitive reconstitution assay
Request a detailed protocolAdult recipient mice were lethally irradiated by a Cesium 137 GammaCell40 Irradiator (MDS Nordia) or an XRAD 320 x-ray irradiator (Precision X-Ray Inc., North Branford, CT) with two doses of 540 rad (total 1080 rad) delivered at least 2 hr apart. Cells were transplanted intravenously into the retro-orbital venous sinus of anesthetized mice. 3 × 105 bone marrow cells were transplanted together with 3 × 105 recipient type competitor cells unless otherwise noted. Mice were maintained on antibiotic water (neomycin sulfate 1.11 g/l and polymixinB 0.121 g/l) for 14 days then switched to regular water. Recipient mice were periodically bled to assess the level of donor-derived blood cells, including myeloid, B and T cells for at least 16 weeks. Blood was subjected to ammonium chloride/potassium red cell lysis before antibody staining. Antibodies including anti-CD45.2 (104), anti-CD45.1 (A20), anti-Gr1 (8C5), anti-Mac-1 (M1/70), anti-B220 (6B2), and anti-CD3 (KT31.1) were used to stain cells for analysis by flow cytometry.
Cell cycle analysis
Request a detailed protocolFor BrdU incorporation assays, mice were given an intraperitoneal injection of 1 mg BrdU (Sigma, St. Louis, MO) per 6 g of body mass in PBS (Phosphate Buffered Saline) and maintained on 1 mg/ml of BrdU in the drinking water for 24 hr (endothelial cells) or 10 days (HSCs). Bone marrow endothelial cells were pre-stained by i.v. injection of Alexa Fluor 555 conjugated anti-VE-cadherin antibody (BV13, eBiosciences). The frequency of BrdU+ cells was then analyzed by flow cytometry using the APC BrdU Flow Kit (BD Biosciences).
Bone sectioning, immunostaining, and confocal imaging
View detailed protocolFreshly dissected bones were fixed in 4% paraformaldehyde overnight followed by 3-day decalcification in 10% EDTA. Bones were sectioned using the CryoJane tape-transfer system (Instrumedics, St. Louis, MO). Sections were blocked in PBS with 10% horse serum for 1 hr and then stained overnight with goat-anti-Angpt1 (Santa Cruz, Dallas, TX, 1:200), chicken-anti-GFP (Aves, Tigard, OR, 1:1000), anti-CD41-PE (eBioscience, clone eBioMWReg30, 1:200) and/or goat-anti-Osteopontin (R&D, Minneapolis, MN, 1:400) antibodies. Donkey-anti-goat Alexa Fluor 647, donkey-anti-chicken Alexa Fluor 488, and/or Donkey-anti-goat Alexa Fluor 555 were used as secondary antibodies (Invitrogen, Grand Island, NY, 1:400). Slides were mounted with anti-fade prolong gold (Invitrogen) and images were acquired with a LSM780 confocal microscope (Zeiss, San Diego, CA). For thick sections, the specimens were cleared overnight with Benzyl Alcohol/Benzyl Benzoate (1:2) solution (Sigma). 3D reconstruction of bone marrow was achieved by Z stack of tiled images of femoral bone marrow with a Zeiss LSM780 confocal microscope.
Quantification of regressed sinusoids
Request a detailed protocolWe defined regressed sinusoids according to the criteria used in a previous publication (Hooper et al., 2009). We analyzed sinusoid morphology in thin optical sections through a segment of the femurs of mice. The sections were transverse sections through the longitudinal axis of the femurs, such that we observed cross-sections through most sinusoids. We first counted the total number of sinusoids in the section. Sinusoids were identified in these sections based on vessel morphology and bright VE-cadherin staining (VE-cadherin staining was dimmer in arterioles and capillaries). We then counted the number of regressed sinusoids in the same sections to arrive at the percentage of regressed sinusoids. Regressed sinusoids (Figure 7D) were distinguished from non-regressed sinusoids (Figure 7C) by being larger in diameter and having few hematopoietic cells around them.
Evans blue extravasation assay
Request a detailed protocolThis assay was modified from a published method (Radu and Chernoff, 2013). Mice were retro-orbitally injected with 200 μl of 0.5% Evans blue in PBS and sacrificed 15 min later. Femurs and spleens were collected, crushed, and then Evans blue in these tissues was eluted in a set volume of PBS. After a brief centrifugation, the concentration of Evans blue in the supernatant was measured on a Nanodrop spectrophotometer (Thermo Scientific, Waltham, MA) at a wavelength of 610 nm. Femurs and spleens from mice without Evans blue injection were used as negative controls and blanks.
Live imaging of calvarial bone marrow
Request a detailed protocolMice were anaesthetized by i.p. injection of ketamine/xylazine. Before imaging, the mice received a retro-orbital injection of 100 μl PBS solution containing 10 μg Alexa Fluor 660 conjugated anti-VE-cadherin antibody (BV13, eBiosciences) and 100 μg Dextran-FITC (70-kDa, Sigma). Then, the mouse was placed on a heated stage with the skull positioned under the objective using a stereotaxic device. Dextran-FITC fluorescence and autofluorescence from bone collagen were captured using two-photon imaging while Alexa Fluor 660-anti-VE-cadherin fluorescence was captured using confocal imaging on the same LSM780 microscope (Zeiss). An approximately 4 × 6 mm area of the calvarium encompassing most of the parasagittal bone marrow cavities within the left and right frontal bones was scanned in each imaging section.
Scanning electron microscopy of bone marrow vasculature
Request a detailed protocolEuthanized mice were pre-fixed by vascular perfusion via the left ventricle for 10 min with a solution containing 2% glutaraldehyde, 2% paraformaldehyde, and 0.1 M cacodylate buffer at pH 7.3. A 1 ml syringe fitted with a 23-gauge needle (BD Biosciences) containing ice-cold PBS was inserted into the growth plate and the then entire marrow plug was gently flushed from the marrow cavity. The marrow plugs were post-fixed in 2.5% glutaraldehyde overnight. They were partially dehydrated in ethanol, fractured in liquid nitrogen, rehydrated, and then fixed in 1% osmium tetroxide for another 2 hr. After full dehydration using a graded series of ethanol concentrations followed by hexamethyldisilazane, the specimens were coated with sliver. Two to three specimens per mouse were randomly chosen and examined on a Zeiss Sigma VP FE-SEM at 5–10 mkV at the UT Southwestern Electron Microscopy Core Facility.
Peptide
Request a detailed protocolCavstratin, a fusion peptide of the putative scaffolding domain of caveolin-1 (amino acids 82–101: DGIWKASFTTFTVTKYWFYR) and the antennapedia internalization sequence (RQIKIWFQNRRMKWKK), was synthesized as previously described (Gratton et al., 2003) at the UT Southwestern Protein Chemistry Technology Center. Peptides were dissolved initially in DMSO and diluted 1000-fold in sterile PBS before in vivo administration (2.5 mg/kg per mouse).
References
-
Control of vascular morphogenesis and homeostasis through the angiopoietin-Tie systemNature Reviews Molecular Cell Biology 10:165–177.https://doi.org/10.1038/nrm2639
-
Signaling and functions of angiopoietin-1 in vascular protectionCirculation Research 98:1014–1023.https://doi.org/10.1161/01.RES.0000218275.54089.12
-
Measurement of megakaryocyte frequency and ploidy distribution in unfractionated murine bone marrowExperimental Hematology 17:278–286.
-
Tie1 deletion inhibits tumor growth and improves angiopoietin antagonist therapyThe Journal of Clinical Investigation 124:824–834.https://doi.org/10.1172/JCI68897
-
Angiopoietin signaling in the vasculatureExperimental Cell Research 319:1271–1280.https://doi.org/10.1016/j.yexcr.2013.03.011
-
Angiopoietins in angiogenesisCancer Letters 328:18–26.https://doi.org/10.1016/j.canlet.2012.08.018
-
Low-dose irradiation promotes tissue revascularization through VEGF release from mast cells and MMP-9-mediated progenitor cell mobilizationThe Journal of Experimental Medicine 202:739–750.https://doi.org/10.1084/jem.20050959
-
Molecular cloning and characterization of mouse TIE and TEK receptor tyrosine kinase genes and their expression in hematopoietic stem cellsBiochemical and Biophysical Research Communications 195:301–309.https://doi.org/10.1006/bbrc.1993.2045
-
Angiopoietin-1 is essential in mouse vasculature during development and in response to injuryThe Journal of Clinical Investigation 121:2278–2289.https://doi.org/10.1172/JCI46322
-
Regeneration of locally irradiated bone marrow. I. Dose dependent, long-term changes in the rat, with particular emphasis upon vascular and stromal reactionBlood 28:398–415.
-
Conditional vascular cell adhesion molecule 1 deletion in mice: impaired lymphocyte migration to bone marrowThe Journal of Experimental Medicine 193:741–754.https://doi.org/10.1084/jem.193.6.741
-
Angiopoietin-1 guides directional angiogenesis through integrin alphavbeta5 signaling for recovery of ischemic retinopathyScience Translational Medicine 5:203ra127.https://doi.org/10.1126/scitranslmed.3006666
-
Angiopoietin-1 suppresses choroidal neovascularization and vascular leakageInvestigative Ophthalmology & Visual Science 55:2191–2199.https://doi.org/10.1167/iovs.14-13897
-
Expression and activity of osteoblast-targeted Cre recombinase transgenes in murine skeletal tissuesThe International Journal of Developmental Biology 48:645–653.https://doi.org/10.1387/ijdb.041816fl
-
Prospective identification, isolation, and systemic transplantation of multipotent mesenchymal stem cells in murine bone marrowThe Journal of Experimental Medicine 206:2483–2496.https://doi.org/10.1084/jem.20091046
-
Requirement for the TIE family of receptor tyrosine kinases in adult but not fetal hematopoiesisProceedings of the National Academy of Sciences of USA 100:12753–12758.https://doi.org/10.1073/pnas.2133552100
-
The receptor tyrosine kinase TIE is required for integrity and survival of vascular endothelial cellsThe EMBO Journal 14:5884–5891.
-
An in vivo assay to test blood vessel permeabilityJournal of Visualized Experiments 16:e50062.https://doi.org/10.3791/50062
-
Tie1, a receptor tyrosine kinase essential for vascular endothelial cell integrity, is not critical for the development of hematopoietic cellsOncogene 12:397–404.
-
High-efficiency deleter mice show that FLPe is an alternative to Cre-loxPNature Genetics 25:139–140.https://doi.org/10.1038/75973
-
Expression of tie-2, a member of a novel family of receptor tyrosine kinases, in the endothelial cell lineageDevelopment 119:957–968.
-
A lymphatic defect causes ocular hypertension and glaucoma in miceThe Journal of Clinical Investigation 124:4320–4324.https://doi.org/10.1172/JCI77162
-
Orchestration of angiogenesis and arteriovenous contribution by angiopoietins and vascular endothelial growth factor (VEGF)Proceedings of the National Academy of Sciences of USA 99:8219–8224.https://doi.org/10.1073/pnas.122109599
Article and author information
Author details
Funding
National Heart, Lung, and Blood Institute (NHBLI) (HL097760)
- Sean J Morrison
Howard Hughes Medical Institute (HHMI) (Investigator)
- Sean J Morrison
Leukemia and Lymphoma Society (LLS) (fellowship)
- Bo O Zhou
Helen Hay Whitney Foundation (HHWF)
- Lei Ding
Howard Hughes Medical Institute (HHMI)
- Lei Ding
The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.
Acknowledgements
SJM is a Howard Hughes Medical Institute (HHMI) Investigator, the Mary McDermott Cook Chair in Pediatric Genetics, the director of the Hamon Laboratory for Stem Cells and Cancer, and a Cancer Prevention and Research Institute of Texas Scholar. This work was supported by the NIH NHLBI (HL097760). BOZ was supported by a fellowship from the Leukemia and Lymphoma Society. LD was supported by a Helen Hay Whitney Foundation Fellowship and by HHMI. We thank T Sanders and E Hughes at the UM transgenic core for helping to generate Angpt1GFP and Angpt1fl mice. We thank the UT Southwestern Protein Chemistry Technology Center for helping to synthesize the Cavtratin peptide. This work was initiated in the Life Sciences Institute at the University of Michigan then completed at Children's Research Institute at UT Southwestern.
Ethics
Animal experimentation: This study was performed in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. All mice were housed at the Unit for Laboratory Animal Medicine at the University of Michigan or in the Animal Resource Center at the University of Texas Southwestern Medical Center. All protocols were approved by the University of Michigan Committee on the Use and Care Animals and by the University of Texas Southwestern Institutional Animal Care and Use Committee (protocol 2011-0104).
Copyright
© 2015, Zhou et al.
This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.
Metrics
-
- 5,753
- views
-
- 1,646
- downloads
-
- 147
- citations
Views, downloads and citations are aggregated across all versions of this paper published by eLife.
Download links
Downloads (link to download the article as PDF)
Open citations (links to open the citations from this article in various online reference manager services)
Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)
Further reading
-
- Stem Cells and Regenerative Medicine
Adult mammals, unlike some lower organisms, lack the ability to regenerate damaged hearts through cardiomyocytes (CMs) dedifferentiation into cells with regenerative capacity. Developing conditions to induce such naturally unavailable cells with potential to proliferate and differentiate into CMs, that is, regenerative cardiac cells (RCCs), in mammals will provide new insights and tools for heart regeneration research. In this study, we demonstrate that a two-compound combination, CHIR99021 and A-485 (2C), effectively induces RCCs from human embryonic stem cell-derived TNNT2+ CMs in vitro, as evidenced by lineage tracing experiments. Functional analysis shows that these RCCs express a broad spectrum of cardiogenesis genes and have the potential to differentiate into functional CMs, endothelial cells, and smooth muscle cells. Importantly, similar results were observed in neonatal rat CMs both in vitro and in vivo. Remarkably, administering 2C in adult mouse hearts significantly enhances survival and improves heart function post-myocardial infarction. Mechanistically, CHIR99021 is crucial for the transcriptional and epigenetic activation of genes essential for RCC development, while A-485 primarily suppresses H3K27Ac and particularly H3K9Ac in CMs. Their synergistic effect enhances these modifications on RCC genes, facilitating the transition from CMs to RCCs. Therefore, our findings demonstrate the feasibility and reveal the mechanisms of pharmacological induction of RCCs from endogenous CMs, which could offer a promising regenerative strategy to repair injured hearts.
-
- Stem Cells and Regenerative Medicine
Bone regeneration is mediated by skeletal stem/progenitor cells (SSPCs) that are mainly recruited from the periosteum after bone injury. The composition of the periosteum and the steps of SSPC activation and differentiation remain poorly understood. Here, we generated a single-nucleus atlas of the periosteum at steady state and of the fracture site during the early stages of bone repair (https://fracture-repair-atlas.cells.ucsc.edu). We identified periosteal SSPCs expressing stemness markers (Pi16 and Ly6a/SCA1) and responding to fracture by adopting an injury-induced fibrogenic cell (IIFC) fate, prior to undergoing osteogenesis or chondrogenesis. We identified distinct gene cores associated with IIFCs and their engagement into osteogenesis and chondrogenesis involving Notch, Wnt, and the circadian clock signaling, respectively. Finally, we show that IIFCs are the main source of paracrine signals in the fracture environment, suggesting a crucial paracrine role of this transient IIFC population during fracture healing. Overall, our study provides a complete temporal topography of the early stages of fracture healing and the dynamic response of periosteal SSPCs to injury, redefining our knowledge of bone regeneration.